GPNX
NOTIFICATION PROCESSED BY IB
10/02/2022
Back to search
Official data from USPTO
HINYE PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
10/02/2022
Trademark type
Combined
Nice classes
5
Filing date
06/28/2021
Registration date
08/02/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/02/2022
Last transaction
08/02/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
CN
Examiner
HELLMAN, ELI J
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The design element appearing to the left of the Chinese characters and wording is comprised of a diamond embedded with a notch and a long curved line. To the right of the design element appears four Chinese characters in horizontal arrangement above the wording HINYE PHARMACY.
Holders and representatives
Holders
Hinye Pharmaceutical Co.,Ltd.
Representatives
Hunan Zhizhou Intellectual Property Services Co., Ltd.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Herbal supplements; medicinal herbal preparations; medicinal herbs; herbs for medicinal purposes; Chinese traditional medicinal herbs; medicinal herbal extracts for medical purposes; medicines for the treatment of gastrointestinal diseases; anti-allergic medicines; medicines for alleviating constipation; pharmaceutical preparations for the treatment of cardiovascular disorderscardiopulmonary disordersneurological disordersimmune system disordersmetabolic disordersrespiratory disordersmusculoskeletal disordersgenitourinary disordersinflammatory disordersdermatological disordersoncological disordershematology disordersophthalmic diseasesallergiespaininflammationsepsisalopeciaobesity and cognitive disorderssexual dysfunctionhormonal disorderspsychiatric disordershepatological disorderscancerwoundsendocrine diseases; pharmaceutical preparations for the prevention of cardiovascular disorderscardiopulmonary disordersneurological disordersimmune system disordersmetabolic disordersrespiratory disordersmusculoskeletal disordersgenitourinary disordersinflammatory disordersdermatological disordersoncological disordershematology disordersophthalmic diseasesallergiespaininflammatory disorderssepsisalopeciaobesity and cognitive disorderssexual dysfunctionhormonal disorderspsychiatric disordershepatological disorderscancerwoundsendocrine diseases; chemical preparations for pharmaceutical or medical purposesfor cardiovascular disorderscardiopulmonary disordersneurological disordersimmune system disordersmetabolic disordersrespiratory disordersmusculoskeletal disordersgenitourinary disordersinflammatory disordersdermatological disordersoncological disordershematology disordersophthalmic diseasesallergiespaininflammation disorderssepsisalopeciaobesity and cognitive disorderssexual dysfunctionhormonal disorderspsychiatric disordershepatological disorderscancerwoundsendocrine diseases; unit dose capsules sold empty for pharmaceutical use; biological preparations for the treatment of cardiovascular disorderscardiopulmonary disordersneurological disordersimmune system disordersmetabolic disordersrespiratory disordersmusculoskeletal disordersgenitourinary disordersinflammatory disordersdermatological disordersoncological disordershematology disordersophthalmic diseasesallergiespaininflammation disorderssepsisalopeciaobesity and cognitive disorderssexual dysfunctionhormonal disorderspsychiatric disordershepatological disorderscancerwoundsendocrine diseases; allergy tablets; antibiotic tablets
Publications
History of USPTO decisions and trademark events.
16 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/15/2022
FIMP
FINAL DISPOSITION PROCESSED
09/15/2022
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
09/01/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
08/02/2022
PUBO
PUBLISHED FOR OPPOSITION
05/17/2022
GPNX
NOTIFICATION PROCESSED BY IB
05/16/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/27/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/27/2022
NPUB
NOTICE OF PUBLICATION
04/27/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/10/2022
DOCK
ASSIGNED TO EXAMINER
03/18/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/02/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
10/30/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/22/2021
Continuous trademark protection
Get notified about every new filing that threatens HINYE PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.